1492 Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

1492 Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-501,050	Closed	-$1.29M	–	125
2022 Q3	$1.29M	Buy	501,050 +11,674	+2%	+$29K	0.93%	37
2022 Q2	$944K	Sell	489,376 -20,452	-4%	-$44.6K	0.62%	55
2022 Q1	$1.51M	Buy	509,828 +18,795	+4%	+$70.7K	0.8%	44
2021 Q4	$2.21M	Buy	491,033 +2,724	+0.6%	+$12.9K	1.09%	32
2021 Q3	$2.37M	Buy	488,309 +361,309	+284%	+$1.99M	1.2%	30
2021 Q2	$866K	Buy	+127,000	New	+$1.03M	0.44%	68

Other funds holding PRTK

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

1492 Capital Management's PRTK Position: Q4 2022 in Review

1492 Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2022, closing a stake of 501,050 shares — an estimated $1.29M sold.

1492 Capital Management first reported a position in PRTK in Q2 2021 and held it in 6 quarters. The position peaked at $2.37M in Q3 2021. 76 funds tracked by Wall St. Rank hold PRTK as of Q4 2022.

1492 Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
1492 Capital Management sold 501,050 Paratek Pharmaceuticals, Inc. shares in Q4 2022, an estimated $1.29M.
1492 Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2021 and held it in 6 quarters.
1492 Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $2.37M in Q3 2021.
76 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2022.

Based on 1492 Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.